Zynerbia Pharmaceuticals Inc. (NASDAQ: ZYNE) has appointed Albert Parker as its Chief Legal Officer and Corporate Sectary to replace Suzanne Hanlon, who is retiring at the...
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has given program updates for autism spectrum disorder(ASD), Fragile X syndrome (FXS), developmental and epileptic encephalopathies (DEE), and 22q11.2 deletion syndrome...
Zynerba Pharmaceutical Inc. (NASDAQ: ZYNE) announced its Q2 2021 financial results and highlighted its recent operations and pipeline update. Zynerba making progress in FXS The company’s...
